AIM: The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively. PATIENTS AND METHODS: This study included 67 patients with pathologic TNM stage II, III, and IV. TYMS and ERCC1 mRNA expression was determined using real-time reverse transcriptase-polymerase chain reaction (RT-PCR). The chemosensitivity was examined using an ATP-based chemotherapy response assay. A high response was defined as a response producing ≥40% reduction in ATP. RESULTS: The mean level of TYMS mRNA expression in the groups with low and high response to 5-FU was 2.35×10(-3) ± 2.16×10(-3) 2(-(ΔCt)) and 4.54×10(-3) ± 2.46×10(-3) 2(-(ΔCt)), respectively. The mean level of ERCC1 mRNA expression in the groups with low and high response to oxaliplatin was 13.92×10(-3) ± 9.90×10(-3) 2(-(ΔCt)) and 23.59×10(-3) ± 5.88×10(-3) 2(-(ΔCt)), respectively. Groups with high response to 5-FU and oxaliplatin had significantly higher expression of TYMS and ERCC1 mRNA, respectively (p<0.01 and p=0.01, respectively). CONCLUSION: High expression of TYMS and ERCC1 mRNA was associated with better in vitro chemosensitivity to 5-FU and oxaliplatin, respectively, in patients with colorectal cancer.
AIM: The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively. PATIENTS AND METHODS: This study included 67 patients with pathologic TNM stage II, III, and IV. TYMS and ERCC1 mRNA expression was determined using real-time reverse transcriptase-polymerase chain reaction (RT-PCR). The chemosensitivity was examined using an ATP-based chemotherapy response assay. A high response was defined as a response producing ≥40% reduction in ATP. RESULTS: The mean level of TYMS mRNA expression in the groups with low and high response to 5-FU was 2.35×10(-3) ± 2.16×10(-3) 2(-(ΔCt)) and 4.54×10(-3) ± 2.46×10(-3) 2(-(ΔCt)), respectively. The mean level of ERCC1 mRNA expression in the groups with low and high response to oxaliplatin was 13.92×10(-3) ± 9.90×10(-3) 2(-(ΔCt)) and 23.59×10(-3) ± 5.88×10(-3) 2(-(ΔCt)), respectively. Groups with high response to 5-FU and oxaliplatin had significantly higher expression of TYMS and ERCC1 mRNA, respectively (p<0.01 and p=0.01, respectively). CONCLUSION: High expression of TYMS and ERCC1 mRNA was associated with better in vitro chemosensitivity to 5-FU and oxaliplatin, respectively, in patients with colorectal cancer.
Authors: Weihua Tang; Douglas R Morgan; Michael O Meyers; Ricardo L Dominguez; Enrique Martinez; Kennichi Kakudo; Pei Fen Kuan; Natalie Banet; Hind Muallem; Kimberly Woodward; Olga Speck; Margaret L Gulley Journal: Infect Agent Cancer Date: 2012-08-28 Impact factor: 2.965
Authors: Christoph Burdelski; Christian Strauss; Maria Christina Tsourlakis; Martina Kluth; Claudia Hube-Magg; Nathaniel Melling; Patrick Lebok; Sarah Minner; Christina Koop; Markus Graefen; Hans Heinzer; Corinna Wittmer; Till Krech; Guido Sauter; Waldemar Wilczak; Ronald Simon; Thorsten Schlomm; Stefan Steurer Journal: Oncotarget Date: 2015-04-10
Authors: Jose J G Marin; Rocio I R Macias; Maria J Monte; Elisa Herraez; Ana Peleteiro-Vigil; Beatriz Sanchez de Blas; Paula Sanchon-Sanchez; Alvaro G Temprano; Ricardo A Espinosa-Escudero; Elisa Lozano; Oscar Briz; Marta R Romero Journal: Cancers (Basel) Date: 2020-09-11 Impact factor: 6.639